AstraZeneca/Array’s AZD6244 Fails Phase II For Melanoma
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms enrolling patients for further trials of the drug candidate in ovarian cancer, hepatocellular and biliary tract carconomas.